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Abstract
Animal studies and premarketing clinical trials have revealed hepato-
toxicity of statins, primarily minor elevations in serum alanine ami-
notransferase levels. The combined chronic use of medicines and
eventual ethanol abuse are common and may present a synergistic
action regarding liver injury. Our objective was to study the effect of
the chronic use of atorvastatin associated with acute ethanol adminis-
tration on the liver in a rat model. One group of rats was treated daily
for 5 days a week for 2 months with 0.8 mg/kg atorvastatin by gavage.
At the end of the treatment the livers were perfused with 72 mM
ethanol for 60 min. Control groups (at least 4 animals in each group)
consisted of a group of 2-month-old male Wistar EPM-1 rats exposed
to 10% ethanol (v/v) ad libitum replacing water for 2 months, followed
by perfusion of the liver with 61 nM atorvastatin for 60 min, and a
group of animals without chronic ethanol treatment whose livers were
perfused with atorvastatin and/or ethanol. The combination of ator-
vastatin with ethanol did not increase the release of injury marker
enzymes (alanine aminotransferase, aspartate aminotransferase, and
lactic dehydrogenase) from the liver and no change in liver function
markers (bromosulfophthalein clearance, and oxygen consumption)
was observed. Our results suggest that the combination of atorvastatin
with ethanol is not more hepatotoxic than the separate use of each
substance.
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Introduction
Familial hypercholesterolemia is one of
the most common genetic disorders with a
prevalence of heterozygotes of about 1/500 in
most western countries (1). The identification
and treatment of patients with hyperlipidemia
play an essential role in the primary and sec-
ondary prevention of coronary heart disease.
Among existing drug therapies, 3-hydroxy-3-
methyl-glutaryl co-enzyme and reductase in-
hibitors, more commonly known as statins,
provide a generally well-tolerated and effec-
tive option for lowering LDL cholesterol lev-
els and decreasing the likelihood of subse-
quent coronary heart disease events (2,3).
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Statins are used chronically and are the most
commercialized class of drugs worldwide
(2,3). Sale perspectives for atorvastatin in
2002 were 8.6 billion dollars (4). Atorvasta-
tin differs from other statins in that it has a
longer action and presents active metabo-
lites which are biotransformed mainly by
CYP3A4 in the liver (5).
Animal studies and premarketing clini-
cal trials point to hepatotoxicity, primarily
minor elevations in serum alanine ami-
notransferase (ALT) levels. For this reason
all cholesterol-lowering drugs have labeling
that requires the monitoring of liver enzymes
(6). The co-factors that modulate statin hepa-
totoxicity have not been completely eluci-
dated (7,8).
In clinical phase IV studies, 0.5% of the
atorvastatin-treated patients showed an in-
crease exceeding three times the normal
aminotransferase activity (9). Even with this
incidence, discontinuation of treatment is
not justified (10). In one premarketing clini-
cal trial with 2045 patients treated with 40 to
80 mg kg-1 day-1 lovastatin, 3.1% of the
patients presented an increase exceeding
three times the normal limit of aminotrans-
ferase activity. Of these patients, 3 reported
alcohol consumption, 2 use of acetamino-
phen, and 4 of acetaminophen and ethanol
(6). In general, patients consuming ethanol
were excluded from the clinical trials.
Combined use of medicines and ethanol
is common and may present a synergistic
action regarding liver injury. There is no
systematic study on the effect of chronic use
of atorvastatin in the presence of eventual
ethanol abuse. Thus, our objective was to
conduct an experimental study exploring this
possibility.
Material and Methods
Animals and study groups
Male Wistar EPM-1 rats from the Ani-
mal House of the Universidade Federal de
São Paulo were manipulated according to
the International Guiding Principles for Bio-
medical Research Involving Animals issued
by the Council for International Organiza-
tion of Medical Sciences. Two-month-old
rats were chronically treated with ethanol or
atorvastatin and, at the end of treatment,
their livers were perfused with atorvastatin
and/or ethanol. The ethanol group received
10% (v/v) ethanol ad libitum 7 days a week
for 2 months, this solution substituting wa-
ter. The atorvastatin group received 0.8 mg/
kg of the drug five times a week for 2 months.
Control groups consisted of 1) a group of
animals exposed to 10% ethanol (v/v) ad
libitum, substituting water, for 2 months at
the end of which period the livers were
perfused with 61 nM atorvastatin for 60 min,
and 2) a group of animals without chronic
treatment whose livers were perfused with
atorvastatin and/or ethanol. At the end of
treatment each group was divided into 4
subgroups according to the drug used in the
liver perfusion experiment: ethanol, ator-
vastatin, ethanol/atorvastatin combination,
and no drug. The initial concentration of 72
mM ethanol added to the perfusion fluid
corresponds to alcoholemia that induces an
euphoric state in humans. The initial con-
centration of atorvastatin (kindly donated by
Laboratórios Pfizer Ltda., São Paulo, SP,
Brazil) in the perfusion fluid was 61 nM
(therapeutic blood level in humans).
Liver perfusion experiments
Monovascular rat liver perfusion was
performed as previously described (11).
Briefly, the rat was perfused with 50 mL
Krebs-Henseleit-bicarbonate buffer contain-
ing 1.5 g/dL hemoglobin, and 1 g/dL bovine
albumin at a 16-mL/min perfusion rate.
Samples of perfusate were collected after 30
min for the determination of oxygen con-
sumption and after 60 min for ALT, aspar-
tate aminotransferase (AST) and lactate de-
hydrogenase (LDH) determinations. After
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Table 1. Alanine aminotransferase (ALT) activity (median, N and range) in samples collected after 60-min
perfusion.
Pretreatment ALT (U L-1 g liver-1) P
Addition to perfusion fluid
None Ethanol Atorvastatin Ethanol and
atorvastatin
None 0.8 (5) (0.3-0.9) 0.9 (5) (0.3-1.7) 0.5 (4) (0.4-0.6) 1.2 (4) (1.0-1.3) 0.04*
Ethanol 1.5 (4) (0.6-3.2) 1.5 (4) (0.7-2.8) 3.7 (4) (3.3-3.7) 1.2 (5) (0.5-4.0)
Atorvastatin 0.6 (4) (0.3-1.2) 0.7 (4) (0.5-9.8) 5.0 (6) (1.9-12.4) 1.3 (5) (1.0-1.8) 0.0137b
P 0.13 0.46 0.0013a 0.70
*No difference observed in the post-test; adifference observed between the samples of the group without
previous treatment and those treated with atorvastatin; bdifference observed between samples of the group
perfused without any drug addition and those perfused with atorvastatin [non-parametric analysis (Kruskal-
Wallis test and Dunn’s post-test)].
Table 2. Aspartate aminotransferase (AST) activity (median, N, and range) in samples collected after 60-min
perfusion.
Pretreatment AST (U L-1 g liver-1)
Addition to perfusion fluid
None Ethanol Atorvastatin Ethanol and atorvastatin
None 1.7 (5) (1.5-1.8) 2.8 (5) (1.8-4.5) 1.7 (4) (0.9-2.2) 1.8 (4) (1.2-5.5)
Ethanol 2.6 (4) (1.44-3.70) 4.8 (4) (2.2-8.0) 3.4 (4) (1.8-4.1) 2.3 (5) (1.3-13.9)
Atorvastatin 1.5 (4) (0.9-3.4) 3.4 (4) (0.7-6.6) 4.7 (6) (1.0-13.0) 1.9 (5) (1.5-2.5)
P 0.39 0.30 0.18 0.52
There were no significant differences between groups [non-parametric analysis (Kruskal-Wallis test and
Dunn’s post-test)].
collection of this last sample, the clearance
of 11 µmol bromosulfophthalein (BSP) was
determined.
Evaluation of liver injury, function, and
histology
In order to determine the degree of liver
injury the following enzymes were deter-
mined in the perfusate: AST, ALT and LDH
(reported as U L-1 g liver-1) using the ADVIA
1650 Chemistry System (Bayer, Munich,
Germany) equipment. Oxygen consumption
is reported as mmol L-1 g liver-1 and BSP
clearance as nmol min-1 g liver-1. At the end
of the experiments, the livers were fixed and
stored for subsequent histological analysis
with hematoxylin-eosin staining.
Results
Liver injury markers
The livers of animals previously treated
with atorvastatin without addition of any
drug to the perfusion fluid did not present an
increase in ALT release, but when perfused
with atorvastatin presented increased ALT
activity in the perfusate. In contrast, the
group perfused with combined ethanol and
atorvastatin did not show an increase in ALT
activity (Table 1).
There was no significant increase in AST
or LDH activity in any group (Tables 2 and 3).
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Table 3. Lactate dehydrogenase (LDH) activity (median, N, and range).
Pretreatment LDH (U L-1 g liver-1)
Addition to perfusion fluid
None Ethanol Atorvastatin Ethanol and atorvastatin
None 26.0 (5) (19.2-47.9) 28.2 (5) (20.6-36.8) 24.2 (4) (17.3-30.1) 16.6 (4) (11.6-50.3)
Ethanol 24.0 (4) (18.1-46.3) 35.2 (4) (19.6-46.3) 22.3 (4) (20.3-55.3) 25.2 (5) (7.3-72.7)
Atorvastatin 19.4 (4) (14.7-25.3) 38.6 (4) (16.7-121.4) 41.6 (6) (17.5-125.7) 28.0 (5) (23.9-42.1)
P 0.33 0.98 0.22 0.58
There were no significant differences between groups [non-parametric analysis (Kruskal-Wallis test and
Dunn’s post-test)].
Table 4. Oxygen consumption (median, N, and range).
Pretreatment Oxygen consumption (mmol L-1 g liver-1)
Addition to perfusion fluid
None Ethanol Atorvastatin Ethanol and atorvastatin
None 0.37 (4) (0.34-0.52) 0.33 (4) (0.21-0.86) 0.45 (4) (0.22-0.55) 0.36 (4) (0.26-0.41)
Ethanol 0.48 (4) (0.28-0.70) 0.54 (4) (0.37-0.62) 0.45 (4) (0.24-0.51) 0.36 (4) (0.25-0.40)
Atorvastatin 0.37 (4) (0.27-0.59) 0.41 (4) (0.12-0.66) 0.34 (4) (0.16-0.40) 0.41 (4) (0.28-0.63)
P 0.67 0.65 0.27 0.63
There were no significant differences between groups [non-parametric analysis (Kruskal-Wallis test and
Dunn’s post-test)].
Evaluation of liver function
There was no difference in oxygen con-
sumption by the liver between the groups
studied (Table 4).
The livers of the animals treated with
atorvastatin and perfused with ethanol pre-
sented a lower BSP clearance rate than the
group which received the same treatment
and was perfused without any drug addition.
Table 5. Bromosulfophthalein (BSP) clearance rate (mean, N, and standard deviation).
Pretreatment BSP clearance rate (nmol min-1 g liver-1) P
Addition to perfusion fluid
None Ethanol Atorvastatin Ethanol and
atorvastatin
None 30.6 (4) (7.5) 26.0 (5) (11.0) 29.7 (4) (1.0) 32.3 (4) (11.5)
Ethanol 28.7 (4) (10.8) 26.9 (4) (7.7) 19.8 (4) (5.6) 33.4 (5) (3.6)
Atorvastatin 22.0 (4) (5.1) 11.5 (4) (2.0) 23.4 (5) (6.8) 26.8 (5) (4.0) 0.0027b
P 0.33 0.0383a 0.07 0.31
aDifference observed between the samples of the group without previous treatment and treated with atorvas-
tatin, both perfused with ethanol. bDifference observed between the samples of the group perfused with
ethanol and its respective control group (previously treated with atorvastatin without addition of the drug to the
perfusion fluid) [parametric analysis (one-way ANOVA and Dunn’s post-test)].
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However, when the perfusion fluid contained
ethanol and atorvastatin this effect was not
observed (Table 5).
Histology
Histological examination of the liver was
normal except for the presence of faint mi-
crovesicular steatosis in the ethanol-treated
group. In the atorvastatin-treated group, rare
focal lymphocyte and monocyte infiltrates
and a slight sinusoid dilatation were ob-
served.
Discussion
Few studies have reported severe ator-
vastatin hepatotoxicity. Nakad et al. (12)
reported a case of atorvastatin-induced acute
hepatitis, and Ridruejo and Mandó (13) re-
ported acute cholestatic hepatitis after reini-
tiating treatment with atorvastatin. Chole-
stasis and hepatitis induced by statin therapy
seem to be rare idiosyncratic reactions (14).
Pelli and Setti (15) suggest that atorvastatin
may trigger autoimmune hepatitis. Only one
case of liver failure was reported by Perger
et al. (16) in 2003. The incidence of in-
creased aminotransferase activity in patients
who consumed high doses of atorvastatin
(80 mg) is 0.5 to 3.3% (17). Although the
experience with the safety of statin therapy
outside clinical trials which establish etha-
nol abuse as an exclusion criterion has not
been fully reported, it is reasonable to sus-
pect that the incidence of side effects may be
higher in clinical situations where patients
are not monitored as closely as they are in
clinical trials (18).
Moderate ethanol consumption (up to 40
g/day) from 3 to 4 times a week provides a
protecting factor against cardiovascular dis-
eases (19). However, the use of combined
medications may alter the biotransformation
of one of them, increasing hepatotoxicity.
Most clinical studies that attempt to prove
the safety of statins do not indicate if the
patients consumed ethanol (10,20-25). Only
Pedersen et al. (26), Newman et al. (27) and
Black et al. (9) considered excessive ethanol
consumption as an exclusion criterion.
Pasternak et al. (8) warned that the concomi-
tant use of ethanol and statins may increase
the risk for myopathies.
Smith et al. (28) conducted a retrospec-
tive review with 1194 patients who con-
sumed statins. Among those who presented
an increase in aminotransferases, only 2 re-
ported ethanol abuse. One of them contin-
ued ethanol consumption, with no change in
aminotransferase activity, and the other
stopped consumption and aminotransferase
activities returned to normal.
In the present study, we did not include a
group of animals chronically treated with
ethanol and atorvastatin. The reason for this
was that, although it has been suggested that
the chronic and abusive use of alcohol reaches
up to 10% of the Brazilian population, 90%
of the population as a whole is not consid-
ered to suffer from alcoholism.
We observed that livers that had contact
with atorvastatin for the first time did not
present an increase in ALT activity in the
perfusate. However, the group of animals
treated and perfused with atorvastatin pre-
sented an increase of this enzyme in the
perfusate. We did not observe a comparable
AST increase, probably because of the dif-
ferent intracellular localization of these en-
zymes. The chronic use of ethanol combined
with acute atorvastatin administration did
not cause an increase in injury marker en-
zymes in the liver (ALT, AST, and LDH,
Tables 1, 2, and 3) nor did it cause a change
in liver function markers (oxygen consump-
tion and BSP clearance, Tables 4 and 5).
The association of chronic atorvastatin
use with acute ethanol abuse also did not
cause an increase of ALT, AST, or LDH
(Tables 1, 2, and 3) or of oxygen consump-
tion (Table 4). However, there was decrease
in the BSP clearance rate in the group where
the liver was perfused with ethanol only
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(Table 5). No ALT increase occurred in
ethanol-treated animals because the dose used
is considered low for this experimental ani-
mal (29). The fact that atorvastatin promoted
an increase in hepatic ALT, but not when
combined with ethanol, deserves further
study for its elucidation.
Our results suggest that the chronic use
of atorvastatin in combination with acute
ethanol abuse is not more toxic than the
separate use of one or the other substance.
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